DE502004001159D1 - Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose - Google Patents

Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose

Info

Publication number
DE502004001159D1
DE502004001159D1 DE502004001159T DE502004001159T DE502004001159D1 DE 502004001159 D1 DE502004001159 D1 DE 502004001159D1 DE 502004001159 T DE502004001159 T DE 502004001159T DE 502004001159 T DE502004001159 T DE 502004001159T DE 502004001159 D1 DE502004001159 D1 DE 502004001159D1
Authority
DE
Germany
Prior art keywords
osteoarthrosis
bradykinin
treatment
receptor antagonists
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE502004001159T
Other languages
English (en)
Inventor
Martin Michaelis
Karl Rudolphi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of DE502004001159D1 publication Critical patent/DE502004001159D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043Kallidins; Bradykinins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE502004001159T 2003-02-07 2004-01-23 Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose Expired - Lifetime DE502004001159D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10304994A DE10304994A1 (de) 2003-02-07 2003-02-07 Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose
PCT/EP2004/000550 WO2004069266A2 (de) 2003-02-07 2004-01-23 Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose

Publications (1)

Publication Number Publication Date
DE502004001159D1 true DE502004001159D1 (de) 2006-09-21

Family

ID=32797325

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10304994A Withdrawn DE10304994A1 (de) 2003-02-07 2003-02-07 Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose
DE502004001159T Expired - Lifetime DE502004001159D1 (de) 2003-02-07 2004-01-23 Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10304994A Withdrawn DE10304994A1 (de) 2003-02-07 2003-02-07 Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose

Country Status (31)

Country Link
EP (1) EP1594520B1 (de)
JP (1) JP2006516980A (de)
KR (1) KR20050105447A (de)
CN (1) CN1317029C (de)
AR (1) AR043036A1 (de)
AT (1) ATE335500T1 (de)
AU (1) AU2004210396A1 (de)
BR (1) BRPI0407333A (de)
CA (1) CA2514152C (de)
CO (1) CO5690613A2 (de)
CY (1) CY1105708T1 (de)
DE (2) DE10304994A1 (de)
DK (1) DK1594520T3 (de)
ES (1) ES2268622T3 (de)
HK (1) HK1085926A1 (de)
HR (1) HRP20050701B1 (de)
IL (1) IL169899A0 (de)
MA (1) MA27618A1 (de)
ME (1) MEP41008A (de)
MX (1) MXPA05007310A (de)
MY (1) MY135827A (de)
NO (1) NO333903B1 (de)
NZ (1) NZ541680A (de)
PE (1) PE20040939A1 (de)
PL (1) PL206412B1 (de)
PT (1) PT1594520E (de)
RS (1) RS51029B (de)
RU (1) RU2329057C2 (de)
TW (1) TW200505472A (de)
WO (1) WO2004069266A2 (de)
ZA (1) ZA200505177B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710522D0 (en) * 2007-06-01 2007-07-11 Royal Veterinary College The Drug delivery system comprising matrix metalloproteinase inhibitors
IT1391236B1 (it) * 2008-07-11 2011-12-01 St Luso Farm D'italia Spa Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63490B1 (en) * 1988-11-24 1995-05-03 Hoechst Ag Peptides having bradykinin antagonist action
MX9100717A (es) * 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
CA2364178C (en) * 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
CA2474645C (en) * 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation

Also Published As

Publication number Publication date
TW200505472A (en) 2005-02-16
EP1594520A2 (de) 2005-11-16
DE10304994A1 (de) 2004-09-02
HRP20050701A2 (en) 2006-09-30
KR20050105447A (ko) 2005-11-04
PL376605A1 (pl) 2006-01-09
ATE335500T1 (de) 2006-09-15
HK1085926A1 (en) 2006-09-08
DK1594520T3 (da) 2006-12-11
MEP41008A (en) 2011-02-10
NZ541680A (en) 2009-07-31
JP2006516980A (ja) 2006-07-13
IL169899A0 (en) 2011-08-01
MXPA05007310A (es) 2005-09-30
CO5690613A2 (es) 2006-10-31
CN1317029C (zh) 2007-05-23
HRP20050701B1 (hr) 2014-01-03
WO2004069266A3 (de) 2004-09-30
AR043036A1 (es) 2005-07-13
CA2514152C (en) 2012-01-17
NO333903B1 (no) 2013-10-14
ES2268622T3 (es) 2007-03-16
MA27618A1 (fr) 2005-11-01
RS51029B (sr) 2010-10-31
PT1594520E (pt) 2006-11-30
ZA200505177B (en) 2006-11-29
RU2329057C2 (ru) 2008-07-20
AU2004210396A1 (en) 2004-08-19
CY1105708T1 (el) 2010-12-22
NO20054144L (no) 2005-09-06
CN1747742A (zh) 2006-03-15
PE20040939A1 (es) 2005-01-17
RU2005127862A (ru) 2006-01-27
EP1594520B1 (de) 2006-08-09
MY135827A (en) 2008-07-31
CA2514152A1 (en) 2004-08-19
WO2004069266A2 (de) 2004-08-19
PL206412B1 (pl) 2010-08-31
RS20050565A (en) 2007-09-21
BRPI0407333A (pt) 2006-01-10

Similar Documents

Publication Publication Date Title
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE371451T1 (de) Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
DE602005019899D1 (de) System zur behandlung von ischämischem schlaganfall
DE60321130D1 (de) Variation von parametern zur neurostimulation
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
ATE366572T1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
ATE367160T1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
DE602004026067D1 (de) Gerät zur Behandlung von Füßen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition